Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 46, n° 2
pages 284-293 (février 2002)
Doi : 10.1067/mjd.2002.119105
Cutaneous manifestations of antiretroviral therapy

Holly A. Ward, MD, Glenn G. Russo, MD, Joseph Shrum, MD
Department of Dermatology, Tulane University School of Medicine. New Orleans, Louisiana 


The pandemic created by HIV, a retrovirus, has stimulated increased research in viral diseases and has generated greater interest in the development of antiretroviral medications. These new medications are presently divided into 3 categories: protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and nucleoside reverse transcriptase inhibitors (NRTIs). These antiretroviral agents carry their own risk for causing adverse reactions, as well as drug interactions. The most recently approved class of antiretrovirals, PIs have been associated with lipodystrophy syndrome, hypersensitivity reactions, urticaria, morbilliform eruptions, and a large number of drug interactions. NNRTIs have resulted in various cutaneous eruptions, as well as a hypersensitivity syndrome. NRTIs have resulted in alterations of the nails, nail and mucocutaneous pigmentation, hair changes, vasculitis, and morbilliform eruptions. This article focuses on the cutaneous manifestations of antiretroviral therapy to help dermatologists recognize them. (J Am Acad Dermatol 2002;46:284-93.)

The full text of this article is available in PDF format.

 Funding sources: None.
 Conflict of interest: None.
 Reprint requests: Holly A. Ward, MD, Tulane University School of Medicine, Department of Dermatology, 1430 Tulane Ave, New Orleans, LA 70112.

© 2002  American Academy of Dermatology, Inc. Published by Elsevier Masson SAS@@#104157@@